July 16, 2206
Sela Breen
For a long time the choices were stark. You take a statin. It doesn’t work? You get poked with an injection every few weeks.
That’s ending. Or at least changing shape.
The FDA has granted priority review to Lipfendra (enlicitide). It is the first oral pill to block a protein called PCSK9. This protein controls how your body handles “bad” cholesterol. Before now drugs that stopped PCSK9 worked too. They were just injections. And people hated them. Not the efficacy, the act itself.
Why block PCSK9?
Your liver makes this protein. Its job? To reduce your body’s ability to scrub LDL cholesterol from your blood. If you stop PCSK9 your liver wakes up. It starts pulling LDL out of circulation. Blood levels drop. It’s simple biology. But the barrier to entry for existing injectable PCSK9 inhibitors was high. Cost, access, and needles are real obstacles for millions. An oral pill removes the needle. Does it remove the cost? Probably not. But it removes a major friction point.
The stakes are high
We aren’t talking about minor tweaks. High LDL is a modifiable risk factor for heart disease. Heart disease kills more Americans than anything else. Too much LDL builds plaques in artery walls. These narrow the arteries. Restrict blood flow. If a plaque ruptures a clot forms. That leads to heart attacks. Strokes. The American College of Cardiology and the American Heart Association set the LDL goal below 50 mg/dL for very high-risk patients. Many people miss that mark.
What the data says
Approval followed two large trials. Total 3207 adults. All had severe high cholesterol. All were already on maximum statin doses.
First trial involved adults with existing cardiovascular disease or high risk. Their average starting LDL sat at 96 mg/dL after 24 weeks the Lipfendra group saw a 56 percent drop compared to placebo.
The second trial focused on those with HeFH (heterozygous familial hypercholessterolemia). A genetic condition that drives LDL way up. Average start? 119 mgd/L. After 24 weeks LDL dropped by 59 percent against placebo.
Current guidance says if you’re on max statins and LDL stays above 70 mg/dA a PCSK9 inhibitor makes sense. A pill that cuts levels by nearly half moves a lot of people closer to the finish line.
“This new drug is not a sal replacement for statins but an add-on.”
Who is this for?
Lipfendra isn’t for everyone. It targets people who’ve failed statin-only therapy. Approved for those with high cholesterol or HeHF who are already doing the lifestyle work diet, exercise, max statins.
Side effects matter. In the HeFH trial patients on Lipfendra reported diarrhea and dizziness more than placebo users. No unique side effects popped up in the heart disease trial, though discontinuation rates were similar. Diarrhea is not ideal. Dizziness is annoying. But for some a pill is preferable to a shot.
Lifestyle first, always
Don’t forget the basics. Guidelines emphasize healthy living before pharmacological therapy. Vegetables, fruits, whole grains, lean protein. 150 minutes a week of moderate exercise.
For many that’s enough. LDL moves in the right direction.
When it’s not enough statins come in.
When statins maxed out don’t hit the target add-ons like Lipfendra enter. This is a ladder. You don’t jump to the top. You climb up. Lipfendra is the next step for those who have genuinely tried the others.
A daily pill that slashes LDL by half is significant. It opens doors. If you or a loved one struggles despite healthy habits and maximum statins talk to your doctor about this approval.
There may still be questions left about long term effects and affordability, but the landscape just shifted slightly. Just a bit.
Sela Breen is Assistant Health Editor at mindbodygreen and a graduate of Northwestern University’s Medill School of Journalism.
